How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Alaska Sees HCV Reduction, But Need For Greater Test-And Treat Adoption Remains

Canine Serology Sheds Light on Underreported Human Coccidioidomycosis Spread

Cefiderocol Demonstrates Better Outcomes as Empiric or Documented Therapy as Compared to Salvage Therapy

Nirmatrelvir-Ritonavir Shows Efficacy for Long COVID, But Lacks Significant Health Improvements

National Youth HIV/AIDS Awareness Day Reminds Young People They Are Not Forgotten

FDA Grants Fast Track Status to ARCT-2304 for H5N1 Influenza Protection

Sweeping Public Health Changes Creates US and Global Turmoil

Study Finds Besifovir a Safer Alternative to Tenofovir for Long-Term Hepatitis B Treatment

Atea Pharmaceuticals Doses First Patient in Phase 3 Trial for Chronic Hepatitis C

Expanding Egypt’s Hepatitis C Elimination Efforts

Schedule an Appointment

Quick Links

Patient Forms

Contact Us